Holen Sie sich die Stockscreener-App
27.36
0.62%
-0.17
Handel nachbörslich:
27.49
0.13
+0.48%
Schlusskurs vom Vortag:
$27.53
Offen:
$27.58
24-Stunden-Volumen:
202.73K
Relative Volume:
0.53
Marktkapitalisierung:
$505.42M
Einnahmen:
$294.28M
Nettoeinkommen (Verlust:
$367.02M
KGV:
1.4467
EPS:
18.9115
Netto-Cashflow:
$75.66M
1W Leistung:
+6.38%
1M Leistung:
-5.23%
6M Leistung:
-5.33%
1J Leistung:
+58.70%
1-Tages-Spanne:
$27.13
$27.95
1-Wochen-Bereich:
$26.27
$28.23
52-Wochen-Spanne:
$15.50
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Firmenname
Rigel Pharmaceuticals
Sektor
Branche
Telefon
650-624-1100
Adresse
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
27.36 | 508.57M | 294.28M | 367.02M | 75.66M | 18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-04-03 | Fortgesetzt | Piper Sandler | Neutral |
| 2022-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-08 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Eingeleitet | B. Riley Securities | Neutral |
| 2020-11-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Fortgesetzt | JP Morgan | Overweight |
| 2019-03-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Eingeleitet | Citigroup | Buy |
| 2018-05-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-31 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Bestätigt | Piper Jaffray | Overweight |
| 2016-07-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Bestätigt | Stifel | Buy |
| 2012-11-29 | Eingeleitet | UBS | Neutral |
| 2012-11-06 | Bestätigt | Oppenheimer | Outperform |
| 2012-03-26 | Eingeleitet | Canaccord Genuity | Hold |
| 2010-12-10 | Herabstufung | MP Advisors | Outperform → Market Perform |
Alle ansehen
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - gurufocus.com
Rigel Pharmaceuticals Inc (FRA:RI2) Stock Price & 30 Year Financial Data - GuruFocus
RIGL PE Ratio & Valuation, Is RIGL Overvalued - Intellectia AI
Rigel Pharmaceuticals (RIGL) seeks approval for equity plan share increases at 2026 meeting - Stock Titan
How (RIGL) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Rigel Pharmaceuticals Balances Breakout Growth With Caution - The Globe and Mail
Why Rigel Pharmaceuticals Shares Tanked - Yahoo
Hennion & Walsh Asset Management Inc. Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Jim Cramer blesses Rigel Pharmaceuticals as a spec as “it’s doing better than people realize” - MSN
Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history - Yahoo Finance Singapore
Rigel Pharmaceuticals, Inc. (RIGL) Stock Price, News, Quote & History - Yahoo! Finance Canada
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Rigel Pharmaceuticals’ pralsetinib shows efficacy in NSCLC clinical trial - tipranks.com
Rigel Pharmaceuticals (RIGL) Reports Promising Results from ARRO - gurufocus.com
Rigel announces publication of final ARROW clinical trial data on Gavreto® (pralsetinib) - marketscreener.com
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology - prnewswire.com
Why Rigel Pharmaceuticals Lost Big in December - AOL.com
Rigel Pharmaceuticals Receives 'Moderate Buy' Rating from Analysts - National Today
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Review: What is the Moat Score of Rigel Pharmaceuticals Inc2026 Highlights & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Jim Cramer Blesses Rigel Pharmaceuticals as a Spec as “It’s Doing Better Than People Realize” - Insider Monkey
Vanguard realignment leads to 0 shares reported for Rigel (RIGL) - Stock Titan
Jim Cramer Broke Down 16 Stocks Including Pharma Plays for Rising Oil - Insider Monkey
Rigel Pharmaceuticals (RIGL) Q4 earnings miss estimates - MSN
Rigel Pharmaceuticals Q4 2025 earnings preview - MSN
Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors - TipRanks
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure - Fierce Biotech
Rigel Pharmaceuticals shows rising relative strength; still shy of key benchmark - MSN
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy? - MSN
Rigel enrols first subject in R289 Phase Ib expansion for MDS - MSN
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update - Quantisnow
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential? - MSN
Rigel Pharmaceuticals jumps on 2025 revenue guidance boost, Q3 beats - msn.com
RIGL stock rises 59% in a year: Time to buy, hold or sell? - MSN
Rigel Pharmaceuticals: Growing Where It Matters (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals (RIGL) earnings expected to grow: Should you buy? - MSN
Assessing Rigel Pharmaceuticals (RIGL) Valuation After Strong Q4 And Full Year 2025 Earnings Results - Sahm
Analysts Set Expectations for RIGL Q3 Earnings - MarketBeat
Surging Earnings Estimates Signal Upside for Rigel (RIGL) Stock - MSN
Rigel Pharmaceuticals (RIGL) EPS Spike On Non Cash Gains Challenges Bullish Narratives - Sahm
Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty - The Globe and Mail
Brokers Offer Predictions for RIGL Q1 Earnings - MarketBeat
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - AOL.com
Rigel Pharmaceuticals (RIGL) Projects Revenue Decline for 2026 - GuruFocus
Rigel Pharma stock slides on 2026 outlook (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap DownWhat's Next? - MarketBeat
Finanzdaten der Rigel Pharmaceuticals-Aktie (RIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rigel Pharmaceuticals-Aktie (RIGL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MOOS WALTER H | Director |
Feb 20 '26 |
Sale |
36.36 |
4,000 |
145,440 |
12,722 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):